Corresponding Author: Eric P. Winer, MD, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (eric_winer@dfci.harvard.edu).
Accepted for Publication: December 10, 2018.
Author Contributions: Drs Waks and Winer had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Both authors.
Acquisition, analysis, or interpretation of data: Waks.
Drafting of the manuscript: Both authors.
Critical revision of the manuscript for important intellectual content: Both authors.
Administrative, technical, or material support: Both authors.
Supervision: Both authors.
Conflict of Interest Disclosures: Dr Winer reported personal fees from Genentech, Roche, Lilly, Tessaro, GlaxoSmithKline, Leap Pharmaceuticals, Carrick Therapeutics, and Jounce Pharmaceuticals and stock options from Verastem outside the submitted work. No other disclosures were reported.
Additional Contributions: We gratefully acknowledge Jennifer Bellon, MD (Dana-Farber Cancer Institute, Boston, Massachusetts), and Tari King, MD (Brigham and Women’s Hospital, Boston, Massachusetts), for their assistance in reviewing portions of this manuscript. They did not receive compensation for their contributions.
1.Bray
F, Ferlay
J, Soerjomataram
I, Siegel
RL, Torre
LA, Jemal
A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018;68(6):394-424. doi:
10.3322/caac.21492PubMedGoogle ScholarCrossref 3.Caughran
J, Braun
TM, Breslin
TM,
et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study.
Breast J. 2018;24(5):730-737. doi:
10.1111/tbj.13034PubMedGoogle ScholarCrossref 4.Morrow
M. Physical examination of the breast. In: Harris
JR, Lippman
ME, Morrow
M, Osborne
CK, eds. Diseases of the Breast. Philadelphia, PA: Wolters Kluwer Health; 2014:chap 3.
5.Dillon
D, Guidi
AJ, Schnitt
SJ. Pathology of invasive breast cancer. In: Harris
JR, Lippman
ME, Morrow
M, Osborne
CK, eds. Diseases of the Breast. 5th ed. Philadelphia, PA: Wolters Kluwer Health; 2014.
6.Joshi
H, Press
MF. Molecular oncology of breast cancer. In: Bland
KI, Copeland
EM, Klimberg
VS, Gradishar
WJ, eds.
The Breast. Philadelphia, PA: Elsevier; 2018:22. doi:
10.1016/B978-0-323-35955-9.00022-2 7.Hammond
ME, Hayes
DF, Dowsett
M,
et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
J Clin Oncol. 2010;28(16):2784-2795. doi:
10.1200/JCO.2009.25.6529PubMedGoogle ScholarCrossref 8.Piccart-Gebhart
MJ, Procter
M, Leyland-Jones
B,
et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med. 2005;353(16):1659-1672. doi:
10.1056/NEJMoa052306PubMedGoogle ScholarCrossref 9.Wolff
AC, Hammond
ME, Hicks
DG,
et al; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
J Clin Oncol. 2013;31(31):3997-4013. doi:
10.1200/JCO.2013.50.9984PubMedGoogle ScholarCrossref 14.Bardia
A, Mayer
IA, Diamond
JR,
et al. Efficacy and Safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer.
J Clin Oncol. 2017;35(19):2141-2148. doi:
10.1200/JCO.2016.70.8297PubMedGoogle ScholarCrossref 16.Robertson
JFR, Llombart-Cussac
A, Feltl
D,
et al. Fulvestrant 500 mg versus anastrazole as first-line treatment for advanced breast cancer: overall survival from the phase II 'first' study. In: San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. Abstract S6-04.
17.Davies
C, Godwin
J, Gray
R,
et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Lancet. 2011;378(9793):771-784. doi:
10.1016/S0140-6736(11)60993-8PubMedGoogle ScholarCrossref 19.Pagani
O, Regan
MM, Walley
BA,
et al; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med. 2014;371(2):107-118. doi:
10.1056/NEJMoa1404037PubMedGoogle ScholarCrossref 20.Francis
PA, Pagani
O, Fleming
GF,
et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer.
N Engl J Med. 2018;379(2):122-137. doi:
10.1056/NEJMoa1803164PubMedGoogle ScholarCrossref 22.Davies
C, Pan
H, Godwin
J,
et al; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet. 2013;381(9869):805-816. doi:
10.1016/S0140-6736(12)61963-1PubMedGoogle ScholarCrossref 23.Gray
RG, Rea
D, Handley
D, Bowden
SJ, Perry
P. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
J Clin Oncol. 2013;31(18 suppl). doi:
10.1200/jco.2013.31.18_suppl.5Google Scholar 26.Gluz
O, Nitz
UA, Christgen
M,
et al. West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment.
J Clin Oncol. 2016;34(20):2341-2349. doi:
10.1200/JCO.2015.63.5383PubMedGoogle ScholarCrossref 28.Jasem
J, Fisher
CM, Amini
A,
et al. The 21-gene recurrence score assay for node-positive, early-stage breast cancer and impact of RxPONDER Trial on chemotherapy decision-making: have clinicians already decided?
J Natl Compr Canc Netw. 2017;15(4):494-503. doi:
10.6004/jnccn.2017.0049PubMedGoogle ScholarCrossref 30.Harris
LN, Ismaila
N, McShane
LM,
et al; American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 2016;34(10):1134-1150. doi:
10.1200/JCO.2015.65.2289PubMedGoogle ScholarCrossref 31.Krop
I, Ismaila
N, Andre
F,
et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update.
J Clin Oncol. 2017;35(24):2838-2847. doi:
10.1200/JCO.2017.74.0472PubMedGoogle ScholarCrossref 32.Albain
KS, Barlow
WE, Shak
S,
et al; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Lancet Oncol. 2010;11(1):55-65. doi:
10.1016/S1470-2045(09)70314-6PubMedGoogle ScholarCrossref 34.Peto
R, Davies
C, Godwin
J,
et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Lancet. 2012;379(9814):432-444. doi:
10.1016/S0140-6736(11)61625-5PubMedGoogle ScholarCrossref 36.Fisher
B, Brown
AM, Dimitrov
NV,
et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
J Clin Oncol. 1990;8(9):1483-1496. doi:
10.1200/JCO.1990.8.9.1483PubMedGoogle ScholarCrossref 37.Henderson
IC, Berry
DA, Demetri
GD,
et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. In: American Society of Clinical Oncology Annual Meeting; May 16-19, 1998; Los Angeles, CA. Abstract 101a.
40.Citron
ML, Berry
DA, Cirrincione
C,
et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
J Clin Oncol. 2003;21(8):1431-1439. doi:
10.1200/JCO.2003.09.081PubMedGoogle ScholarCrossref 41.Gray
R, Bradley
R, Braybrooke
J,
et al. Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis. In: San Antonio Breast Cancer Symposium; December 5-7, 2017; San Antonio, TX. Abstract GS1-01.
42.Jones
S, Holmes
FA, O’Shaughnessy
J,
et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735.
J Clin Oncol. 2009;27(8):1177-1183. doi:
10.1200/JCO.2008.18.4028PubMedGoogle ScholarCrossref 45.von Minckwitz
G, Loibl
S, Schneeweiss
A,
et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). In: San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. Abstract S2-04.
46.Sikov
WM, Berry
DA, Perou
CM,
et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/− carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). In: San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. Abstract S2–05.
51.Pivot
X, Romieu
G, Debled
M,
et al; PHARE trial investigators. 6 Months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol. 2013;14(8):741-748. doi:
10.1016/S1470-2045(13)70225-0PubMedGoogle ScholarCrossref 52.Cameron
D, Piccart-Gebhart
MJ, Gelber
RD,
et al; Herceptin Adjuvant (HERA) Trial Study Team. 11 Years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet. 2017;389(10075):1195-1205. doi:
10.1016/S0140-6736(16)32616-2PubMedGoogle ScholarCrossref 53.Earl
HM, Hiller
L, Vallier
A-L,
et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
J Clin Oncol. 2018;36(15_suppl). doi:
10.1200/JCO.2018.36.15_suppl.506Google Scholar 56.von Minckwitz
G, Procter
M, de Azambuja
E,
et al; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.
N Engl J Med. 2017;377(2):122-131. doi:
10.1056/NEJMoa1703643PubMedGoogle ScholarCrossref 57.Martin
M, Holmes
FA, Ejlertsen
B,
et al; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017;18(12):1688-1700. doi:
10.1016/S1470-2045(17)30717-9PubMedGoogle ScholarCrossref 58.Fisher
B, Anderson
S, Bryant
J,
et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
N Engl J Med. 2002;347(16):1233-1241. doi:
10.1056/NEJMoa022152PubMedGoogle ScholarCrossref 59.Krag
DN, Anderson
SJ, Julian
TB,
et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Lancet Oncol. 2010;11(10):927-933. doi:
10.1016/S1470-2045(10)70207-2PubMedGoogle ScholarCrossref 60.Krag
DN, Anderson
SJ, Julian
TB,
et al; National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
Lancet Oncol. 2007;8(10):881-888. doi:
10.1016/S1470-2045(07)70278-4PubMedGoogle ScholarCrossref 61.Giuliano
AE, Hunt
KK, Ballman
KV,
et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
JAMA. 2011;305(6):569-575. doi:
10.1001/jama.2011.90PubMedGoogle ScholarCrossref 62.Donker
M, van Tienhoven
G, Straver
ME,
et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Lancet Oncol. 2014;15(12):1303-1310. doi:
10.1016/S1470-2045(14)70460-7PubMedGoogle ScholarCrossref 63.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Lancet Oncol. 2018;19(1):27-39. doi:
10.1016/S1470-2045(17)30777-5PubMedGoogle ScholarCrossref 66.Darby
S, McGale
P, Correa
C,
et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Lancet. 2011;378(9804):1707-1716. doi:
10.1016/S0140-6736(11)61629-2PubMedGoogle ScholarCrossref 68.Haviland
JS, Owen
JR, Dewar
JA,
et al; START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Lancet Oncol. 2013;14(11):1086-1094. doi:
10.1016/S1470-2045(13)70386-3PubMedGoogle ScholarCrossref 69.Coles
CE, Griffin
CL, Kirby
AM,
et al; IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet. 2017;390(10099):1048-1060. doi:
10.1016/S0140-6736(17)31145-5PubMedGoogle ScholarCrossref 71.Bartelink
H, Horiot
JC, Poortmans
PM,
et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial.
J Clin Oncol. 2007;25(22):3259-3265. doi:
10.1200/JCO.2007.11.4991PubMedGoogle ScholarCrossref 72.Hughes
KS, Schnaper
LA, Bellon
JR,
et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
J Clin Oncol. 2013;31(19):2382-2387. doi:
10.1200/JCO.2012.45.2615PubMedGoogle ScholarCrossref 73.Kunkler
IH, Williams
LJ, Jack
WJ, Cameron
DA, Dixon
JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
Lancet Oncol. 2015;16(3):266-273. doi:
10.1016/S1470-2045(14)71221-5PubMedGoogle ScholarCrossref 74.McGale
P, Taylor
C, Correa
C,
et al; EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
Lancet. 2014;383(9935):2127-2135. doi:
10.1016/S0140-6736(14)60488-8PubMedGoogle ScholarCrossref 76.Poortmans
PM, Collette
S, Kirkove
C,
et al; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer.
N Engl J Med. 2015;373(4):317-327. doi:
10.1056/NEJMoa1415369PubMedGoogle ScholarCrossref 84.Tutt
A, Ellis
P, Kilburn
L,
et al. The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. In: San Antonio Breast Cancer Symposium; December 9-13, 2014. Abstract S3-01.
85.Cardoso
F, Bedard
PL, Winer
EP,
et al; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
J Natl Cancer Inst. 2009;101(17):1174-1181. doi:
10.1093/jnci/djp235PubMedGoogle ScholarCrossref 87.von Minckwitz
G, du Bois
A, Schmidt
M,
et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study.
J Clin Oncol. 2009;27(12):1999-2006. doi:
10.1200/JCO.2008.19.6618PubMedGoogle ScholarCrossref 88.Sledge
GW
Jr, Toi
M, Neven
P,
et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy.
J Clin Oncol. 2017;35(25):2875-2884. doi:
10.1200/JCO.2017.73.7585PubMedGoogle ScholarCrossref 94.Ben-Baruch
NE, Bose
R, Kavuri
SM, Ma
CX, Ellis
MJ. HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor.
J Natl Compr Canc Netw. 2015;13(9):1061-1064. doi:
10.6004/jnccn.2015.0131PubMedGoogle ScholarCrossref 101.Jones
SE, Savin
MA, Holmes
FA,
et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
J Clin Oncol. 2006;24(34):5381-5387. doi:
10.1200/JCO.2006.06.5391PubMedGoogle ScholarCrossref 103.Slamon
DJ, Neven
P, Chia
S,
et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3.
J Clin Oncol. 2018;36(24):2465-2472. doi:
10.1200/JCO.2018.78.9909PubMedGoogle ScholarCrossref